Pharmacological therapeutics in Friedreich ataxia: the present state

References

• Lynch DR, Farmer JM, Balcer LJ, et al. Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy. Arch Neurol. 2002;59(5):743–747.
   PubMed Web of Science ®Google Scholar
• Harding AE. Friedreich’s ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain. 1981;104(3):589–620.
   PubMed Web of Science ®Google Scholar
• Parkinson MH, Boesch S, Nachbauer W, et al. Clinical features of Friedreich’s ataxia: classical and atypical phenotypes. J Neurochem. 2013;126(Suppl.1):103–117.
   PubMed Web of Science ®Google Scholar
• Stolle CA, Frackelton EC, McCallum J, et al. Novel, complex interruptions of the GAA repeat in small, expanded alleles of two affected siblings with late-onset. Friedreich Ataxia. 2008;23:1303–1306.
   Google Scholar
• Dürr A, Cossee M, Agid Y, et al. Clinical and genetic abnormalities in patients with Friedreich’s ataxia. N Engl J Med. 1996;335(16):169–1175.
   Web of Science ®Google Scholar
• Tsou AY, Paulsen EK, Lagedrost SJ, et al. Mortality in Friedreich ataxia. J Neurol Sci. 2011;307(1–2):46–49.
   PubMed Web of Science ®Google Scholar
• Nachbauer W, Bodner T, Boesch S, et al. Friedreich ataxia: executive control is related to disease onset and GAA repeat length. Cerebellum. 2014;13(1):9–16.
   PubMed Web of Science ®Google Scholar
• Corben LA, Klopper F, Stagnitti M, et al. Measuring inhibition and cognitive flexibility in Friedreich ataxia. Cerebellum. 2017;16(4):757–763.
   PubMed Web of Science ®Google Scholar
• Campuzano V, Montermini L, Moltò MD, et al. Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271(5254):1423–1427.
   PubMed Web of Science ®Google Scholar
• Pandolfo M. Molecular pathogenesis of Friedreich ataxia. Arch Neurol. 1999;56(10):1201–1208.
   PubMedGoogle Scholar
• Metz G, Coppard N, Cooper JM, et al. Rating disease progression of Friedreich’s ataxia by the International Cooperative Ataxia Rating Scale: analysis of a 603-patient database. Brain. 2013;136(Pt 1):259–268.
   PubMed Web of Science ®Google Scholar
• Friedman LS, Farmer JM, Perlman S, et al. Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design. Mov Disord. 2010;25(4):426–432.
   PubMed Web of Science ®Google Scholar
• Patel M, Isaacs CJ, Seyer L, et al. Progression of Friedreich ataxia: quantitative characterization over 5 years. Ann Clin Transl Neurol. 2016;3:684–694.
   PubMed Web of Science ®Google Scholar
• Reetz K, Dogan I, Costa AS, et al. Biological and clinical characteristics of the European Friedreich’s Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data. Lancet Neurol. 2015;14:174–182.
   PubMed Web of Science ®Google Scholar
• Reetz K, Dogan I, Hilgers RD, et al. Progression characteristics of the European Friedreich’s Ataxia Consortium for Translational Studies (EFACTS): a 2 year cohort study. Lancet Neurol. 2016;15:1346–1354.
   PubMed Web of Science ®Google Scholar
• Chiang S, Kovacevic Z, Sahni S, et al. Frataxin and the molecular mechanism of mitochondrial iron-loading in Friedreich’s ataxia. Clin Sci (Lond.). 2016;130(11):853–870.
   PubMed Web of Science ®Google Scholar
• González-Cabo P, Palau F. Mitochondrial pathophysiology in Friedreich’s ataxia. J Neurochem. 2013;126(Suppl 1):53–64.
   PubMed Web of Science ®Google Scholar
• Trouillas P, Takayanagi T, Hallett M, et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci. 1997;145(2):205–211.
   PubMed Web of Science ®Google Scholar
• Subramony SH, May W, Lynch D, et al. Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale. Neurology. 2005;64(7):1261–1262.
   PubMed Web of Science ®Google Scholar
• Lynch DR, Farmer JM, Tsou AY, et al. Measuring Friedreich ataxia: complementary features of examination and performance measures. Neurology. 2006;66(11):1711–1716.
   PubMed Web of Science ®Google Scholar
• Bürk K, Mälzig U, Wolf S, et al. Comparison of three clinical rating scales in Friedreich ataxia (FRDA). Mov Disord. 2009;24(12):1779–1784.
   PubMed Web of Science ®Google Scholar
• Suno M, Nakaoka A. Inhibition of lipid peroxidation by a novel compound, idebenone (CV-2619). Jap J Pharmacol. 1984;35(2):196–198.
   PubMedGoogle Scholar
• Parkinson MH, Schulz JB, Giunti P. Co-enzyme Q10 and idebenone use in Friedreich’s ataxia. J Neurochem. 2013;126(Suppl. 1):125–141.
   PubMed Web of Science ®Google Scholar
• Myers L, Farmer JM, Wilson RB, et al. Antioxidant use in Friedreich ataxia. J Neurol Sci. 2008;267(1–2):174–176.
   PubMed Web of Science ®Google Scholar
• Strawser CJ, Schadt KA, Lynch DR. Therapeutic approaches for the treatment of Friedreich’s ataxia. Expert Rev Neurother. 2014;14(8):949–957.
   PubMed Web of Science ®Google Scholar
• Rustin P, von Kleist-Retzow JC, Chantrel-Groussard K, et al. Effect of idebenone on cardiomyopathy in Friedreich’s ataxia: a preliminary study. Lancet. 1999;354(9177):477–479.
   PubMed Web of Science ®Google Scholar
• Hausse AO, Aggoun Y, Bonnet D, et al. Idebenone and reduced cardiac hypertrophy in Friedreich’s ataxia. Heart. 2002;87(4):346–349.
   PubMed Web of Science ®Google Scholar
• Buyse G, Mertens L, Di Salvo G, et al. Idebenone treatment in Friedreich’s ataxia: neurological, cardiac, and biochemical monitoring. Neurology. 2003;60(10):1679–1681.
   PubMed Web of Science ®Google Scholar
• Lagedrost SJ, Sutton MS, Cohen MS, et al. Idebenone in Friedreich ataxia cardiomyopathy—results from a 6-month phase III study (IONIA). Am Heart J. 2011;161(3):639–645.
   PubMed Web of Science ®Google Scholar
• Artuch R, Aracil A, Mas A, et al. Friedreich’s ataxia: idebenone treatment in early stage patients. Neuropediatrics. 2002;33(4):190–193.
   PubMed Web of Science ®Google Scholar
• Pineda M, Arpa J, Montero R, et al. Idebenone treatment in paedeatric and adult patients with Friedreich’s ataxia: long-term follow-up. Eur J Paediatr Neurol. 2008;12(6):470–475.
   PubMed Web of Science ®Google Scholar
• Lynch DR, Perlman SL, Meier, T. A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia. Arch Neurol. 2010;67(8):941–947.
   PubMed Web of Science ®Google Scholar
• Lodi R, Hart PE, Rajagopalan B, et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich’s ataxia. Ann Neurol. 2001;49(5):590–596.
   PubMed Web of Science ®Google Scholar
• Cooper JM, Schapira AH. Friedreich’s ataxia: disease mechanisms, antioxidant and coenzyme Q10 therapy. Biofactors. 2003;18(1–4):163–171.
   PubMed Web of Science ®Google Scholar
• Hart PE, Lodi R, Rajagopalan B, et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol. 2005;62(4):621–626.
   PubMedGoogle Scholar
• Lynch DR, Willi SM, Wilson RB, et al. A0001 in Friedreich ataxia: biochemical characterization and effects in a clinical trial. Mov Disord. 2012;27(8):1026–1033.
   PubMed Web of Science ®Google Scholar
• Martinelli D, Catteruccia M, Piemonte F, et al. EPI-743 reverses the progression of the pediatric mitochondrial diseases—genetically defined Leigh syndrome. Mol Genet Metab. 2010;107(3):383–388.
   Web of Science ®Google Scholar
• Sadun AA, Chicani CF, Ross-Cisneros FN, et al. Effect of EPI-743 on the clinical course of the mitochondrial disease Leber hereditary optic neuropathy. Arch Neurol. 2012;69(3):331–338.
   PubMed Web of Science ®Google Scholar
• Enns GM, Kinsman SL, Perlman SL, et al. Initial experience in the treatment of inherited mitochondrial disease with EPI-743. Mol Genet Metab. 2012;105(1):91–102.
   PubMed Web of Science ®Google Scholar
• Zesiewicz T, Perlman S, Sullivan K, et al. EPI-743 (alpha-tocotrienol quinone) demonstrates long-term improvement in neurological function and disease progression in Friedreich’s ataxia (S17.005). Neurology. 2017;88(16):SupplementS17.005.
   Google Scholar
• Sullivan K, Freeman M, Shaw J, et al. EPI-743 for Friedreichs ataxia patients with point mutations. Neurology. 2016;86(16):Supplement P5.388.
   Google Scholar
• Elsden SR, Hilton MG, Waller JM. The end products of the metabolism of aromatic amino acids by clostridia. Arch Microbiol. 1976;107:283–288.
   PubMed Web of Science ®Google Scholar
• Bendheim PE, Poeggeler B, Neria E, et al. Development of indole-3-propionic acid (OXIGON) for Alzheimer’s disease. J Mol Neurosci. 2002;19(1–2):213–217.
   PubMed Web of Science ®Google Scholar
• Hwang IK, Yoo KY, Li H, et al. Indole-3-propionic acid attenuates neuronal damage and oxidative stress in the ischemic hippocampus. J Neurosci Res. 2009;87(9):2126–2137.
   PubMed Web of Science ®Google Scholar
• Chyan YJ, Poeggeler B, Omar RA, et al. Potent neuroprotective properties against the Alzheimer beta-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid. J Biol Chem. 1999;274(31):21937–21942.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov: Safety and Pharmacology Study of VP 20629 in Adults With Friedreich’s Ataxia. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01898884?term=vp-20629&rank=1
   Google Scholar
• Cotticelli MG, Crabbe AM, Wilson RB, et al. Insights into the role of oxidative stress in the pathology of Friedreich ataxia using peroxidation resistant polyunsaturated fatty acids. Redox Biol. 2013;1:398–404.
   PubMed Web of Science ®Google Scholar
• Shchepinov MS, Chou VP, Pollock E, et al. Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson’s disease. Toxicol Lett. 2011;207(2):97–103.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov A First in Human Study of RT001 in Patients With Friedreich’s Ataxia. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02445794
   Google Scholar
• Retrotope Announces Phase I/II Clinical Trial Results of RT001 in Treatment of Friedreich’s Ataxia. Available from: https://static1.squarespace.com/static/549af14ae4b004237f7bb71a/t/57dd7786f7e0ab741930775f/1474131955350/PR±Retrotope±Phase±1±Results.pdf
   Google Scholar
• FARA Research pipeline. Available from: www.curefa.org/pipeline.html
   Google Scholar
• Costantini A, Laureti T, Pala MI, et al. Long-term treatment with thiamine as possible medical therapy for Friedreich ataxia. J Neurol. 2016;263(11):2170–2178.
   PubMed Web of Science ®Google Scholar
• Breuer W, Ermers MJ, Pootrakul P, et al. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood. 2001;97:792–798.
   PubMed Web of Science ®Google Scholar
• Koeppen AH, Ramirez RL, Becker AB, et al. The pathogenesis of cardiomyopathy in Friedreich ataxia. PLoS. 2006;10(3):e0116396.
   Google Scholar
• Smith JC, Kushner JP, Bromberg M. et al. Evidence for mitochondrial iron overload in patients with Friedreich’s ataxia. Proceedings of the Friedreich’s Ataxia Research Conference; Bethesda (MD): National Institutes of Health; 1999.
   Google Scholar
• Pandolfo M, Hausmann L. Deferiprone for the treatment of Friedreich’s ataxia. J Neurochem. 2013;126(Suppl 1):142–146.
   PubMed Web of Science ®Google Scholar
• Velasco-Sánchez D, Aracil A, Montero R, et al. Combined therapy with idebenone and deferiprone in patients with Friedreich’s ataxia. Cerebellum. 2011;10(1):1–8.
   PubMed Web of Science ®Google Scholar
• Arpa J, Sanz-Gallego I, Rodríguez-de-Rivera FJ, et al. Triple therapy with deferiprone, idebenone and riboflavin in Friedreich’s ataxia - open-label trial. Acta Neurol Scand. 2014;129:32–40.
   PubMed Web of Science ®Google Scholar
• Wilson RB, Lynch DR, Fischbeck KH. Normal serum iron and ferritin concentrations in patients with Friedreich’s ataxia. Ann Neurol. 1998;44:132–134.
   PubMed Web of Science ®Google Scholar
• Coppola G, Marmolino D, Lu D, et al. Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARgamma pathway as a therapeutic target in Friedreich’s ataxia. Hum Mol Genet. 2009;18(13):2452–2461.
   PubMed Web of Science ®Google Scholar
• Marmolino D, Manto M, Acquaviva F, et al. PGC-1alpha down-regulation affects the antioxidant response in Friedreich’s ataxia. PLoS One. 2010;5(4):e10025.
   PubMed Web of Science ®Google Scholar
• Shin JH, Ko HS, Kang H, et al. PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson’s disease. Cell. 2011;144(5):689–702.
   PubMed Web of Science ®Google Scholar
• Holmström K, Kostov R, Dinkova-Kostova A. The multifaceted role of Nrf2 in mitochondrial function. Curr Opin Toxicol. 2016;1:80–91.
   PubMedGoogle Scholar
• Probst BL, Trevino I, McCauley L, et al. RTA 408, A novel synthetic triterpenoid with broad anticancer and anti-inflammatory activity. PLoS ONE. 2015;10(4):e0122942.
   PubMed Web of Science ®Google Scholar
• Chen PC, Vargas MR, Pank AK, et al. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson’s disease: critical role for the astrocyte. Proc Natl Acad Sci USA. 2009;106:2933–2938.
   PubMed Web of Science ®Google Scholar
• Kim HV, Kim HY, Ehrlich HY, et al. Amelioration of Alzheimer’s disease by neuroprotective effect of sulforaphane in animal model. Amyloid. 2013;20:7–12.
   PubMed Web of Science ®Google Scholar
• Quinti L, Casale M, Moniot S, et al. SIRT2- and NRF2-targeting thiazole-containing compound with therapeutic activity in Huntington’s disease models. Cell Chem Biol. 2016;23:849–861.
   PubMed Web of Science ®Google Scholar
• D’Oria V, Petrini S, Travaglini L, et al. Frataxin deficiency leads to reduced expression and impaired translocation of NF-E2-related factor (Nrf2) in cultured motor neurons. Int J Mol Sci. 2013;14:7853–7865.
   PubMed Web of Science ®Google Scholar
• Paupe V, Dassa EP, Goncalves S, et al. Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia. PLoS One. 2009;4:4253–4264.
   PubMed Web of Science ®Google Scholar
• Shan Y, Schoenfeld RA, Hayashi G, et al. Frataxin deficiency leads to defects in expression of antioxidants and Nrf2 expression in dorsal root ganglia of the Friedreich’s ataxia YG8R mouse model. Antioxid Redox Signal. 2013;19:131481–131493.
   Web of Science ®Google Scholar
• Albeti R, Uzun E, Renganathan I, et al. Targeting lipid peroxidation and mitochondrial imbalance in Friedreich’s ataxia. Pharmacol Res. 2015;99:344–350.
   PubMed Web of Science ®Google Scholar
• Sahdeo S, Scott BD, McMackin MZ, et al. Dyclonine rescues frataxin deficiency in animal models and buccal cells of patients with Friedreich’s ataxia. Hum Mol Genet. 2014;23(25):6848–6862.
   PubMed Web of Science ®Google Scholar
• Reata Pharmaceuticals, Inc. Announces positive data from part one of moxie trial of omaveloxolone for Friedreich’s ataxia. Available from: http://investors.reatapharma.com/phoenix.zhtml?c=254306&p=irol-newsArticle&ID=2278245
   Google Scholar
• Yiu EM, Tai G, Peverill RE, et al. An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels. J Neurol. 2015;262(5):1344–1353.
   PubMed Web of Science ®Google Scholar
• Smoliga JM, Blanchard O. Enhancing the delivery of resveratrol in humans: if low bioavailability is the problem, what is the solution? Molecules. 2014;19(11):17154–17172.
   PubMed Web of Science ®Google Scholar
• Sturm B, Stupphann D, Kaun C, et al. Recombinant human erythropoietin: effects on frataxin expression in vitro. Eur J Clin Invest. 2005;35(11):711–717.
   PubMed Web of Science ®Google Scholar
• Boesch S, Sturm B, Hering S, et al. Neurological effects of recombinant human erythropoietin in Friedreich’s ataxia: a clinical pilot trial. Mov Disord. 2008;23(13):1940–1944.
   PubMed Web of Science ®Google Scholar
• Saccà F, Piro R, De Michele G, et al. Epoetin alfa increases frataxin production in Friedreich’s ataxia without affecting hematocrit. Mov Disord. 2011;26(4):739–742.
   PubMed Web of Science ®Google Scholar
• Nachbauer W, Hering S, Seifert M, et al. Effects of erythropoietin on frataxin levels and mitochondrial function in Friedreich ataxia–a dose-response trial. Cerebellum. 2011;10(4):763–769.
   PubMed Web of Science ®Google Scholar
• Mariotti C, Fancellu R, Caldarazzo S, et al. Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial. Mov Disord. 2012;27(3):446–449.
   PubMed Web of Science ®Google Scholar
• Boesch S, Nachbauer W, Mariotti C, et al. Safety and tolerability of carbamylated erythropoietin in Friedreich’s ataxia. Mov Disord. 2014;29:935–939.
   PubMed Web of Science ®Google Scholar
• Miller JL, Rai M, Frigon NL, et al. Erythropoietin and small molecule agonists of the tissue-protective erythropoietin receptor increase FXN expression in neuronal cells in vitro and in Fxn-deficient KIKO mice in vivo. Neuropharmacology. 2017;123:34–45.
   PubMed Web of Science ®Google Scholar
• Tomassini B, Arcuri G, Fortuni S, et al. Interferon gamma upregulates frataxin and corrects the functional deficits in a Friedreich ataxia model. Hum Mol Genet. 2012;21(13):2855–2861.
   PubMed Web of Science ®Google Scholar
• Seyer L, Greeley N, Foerster D, et al. Open label pilot study of interferon gamma-1b in Friedreich ataxia. Acta Neurol Scand. 2014;132(1):7–15.
   PubMed Web of Science ®Google Scholar
• Wells M, Seyer L, Schadt K, et al. IFN-y for Friedreich ataxia: present evidence. Neurodegener Dis Manag. 2015;5(6):497–504.
   PubMed Web of Science ®Google Scholar
• Marcotulli C, Fortuni S, Arcuri G, et al. GIFT-1, a phase IIa clinical trial to test the safety and efficacy of IFN-y administration in FRDA patients. Neurol Sci. 2016;37(3):361–364.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich’s Ataxia (STEADFAST). Available from: https://www.clinicaltrials.gov/ct2/show/NCT02415127
   Google Scholar
• Horizon Pharma: Horizon Pharma plc Announces Topline Results from Phase 3 Study of ACTIMMUNE® (interferon gamma-1b) in Friedreich’s Ataxia. Available from: http://ir.horizon-pharma.com/releasedetail.cfm?ReleaseID=1003338
   Google Scholar
• Vyas PM, Tomamichel WJ, Pride PM, et al. A TAT-Frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich’s ataxia mouse model. Hum Mol Genet. 2011;21.6:1230–1247.
   Web of Science ®Google Scholar
• Kim MJ, Kim DW, Jeong HJ, et al. Tat-frataxin protects dopaminergic neuronal cells against MPTP-induced toxicity in a mouse model of Parkinson’s disease. Biochimie. 2012;94:2448–2456.
   PubMed Web of Science ®Google Scholar
• Nabhan JF, Wood KM, Rao VP, et al. Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich’s ataxia. Sci Rep. 2016;6:20019.
   PubMed Web of Science ®Google Scholar
• Kemp K, Serminara N, Hares K, et al. Cytokine therapy-mediated neuroprotection in a Friedreich’s ataxia mouse model. Ann Neurol. 2017;81(2):212–226.
   PubMed Web of Science ®Google Scholar
• Rufini A, Cavallo F, Condò I, et al. Highly specific ubiquitin-competing molecules effectively promote frataxin accumulation and partially rescue the aconitase defect in Friedreich ataxia cells. Neurobiol Dis. 2015;75:91–99.
   PubMed Web of Science ®Google Scholar
• Benini M, Fortuni S, Condò I, et al. E3 ligase RNF126 directly ubiquitinates frataxin, promoting its degradation: identification of a potential therapeutic target for Friedreich ataxia. Cell Rep. 2017;18(8):2007–2017.
   PubMed Web of Science ®Google Scholar
• Nabhan JF, Gooch RL, Piatnitski Chekler EL, et al. Perturbation of cellular proteostasis networks identifies pathways that modulate precursor and intermediate but not mature levels of frataxin. Sci Rep. 2015;5:18251.
   PubMed Web of Science ®Google Scholar
• Clark E, Butler J, Isaacs C, et al. Selected missense mutations impair frataxin processing in Friedreich ataxia. Annals Clin and Trans Neurol. 2017. DOI:10.1002/acn3.433
   PubMed Web of Science ®Google Scholar
• Soragni E, Xu C, Plasterer HL, et al. Rationale for the development of 2-aminobenzamide histone deacetylase inhibitors as therapeutics for Friedreich ataxia. J Child Neurol. 2012;27(9):1164–1173.
   PubMed Web of Science ®Google Scholar
• Chutake YK, Lam CC, Costello WN, et al. Reversal of epigenetic promoter silencing in Friedreich ataxia by a class I histone deacetylase inhibitor. Nucleic Acids Res. 2016;44(11):5095–5104.
   PubMed Web of Science ®Google Scholar
• Coedazzi F, Hu A, Rai M, et al. Friedreich ataxia-induced pluripotent stem cell-derived neurons show a cellular phenotype that is corrected by a benzamide HDAC inhibitor. Hum Mol Genet. 2016;25(22):4847–4855.
   PubMed Web of Science ®Google Scholar
• Rai M, Soragni E, Jenssen K, et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS One. 2008;3(4):e1958.
   PubMed Web of Science ®Google Scholar
• Soragni, E, Miao W, Iudicello M, et al. Epigenetic therapy for Friedreich ataxia. Ann Neurol. 2014;76:489–508.
   PubMed Web of Science ®Google Scholar
• Chan PK, Torres R, Yandim C, et al. Heterochromatinization induced by GAA-repeat hyperexpansion in Friedreich’s ataxia can be reduced upon HDAC inhibition by vitamin B3. Hum Mol Genet. 2013;22(13):2662–2675.
   PubMed Web of Science ®Google Scholar
• Libri V, Yandim C, Athanasopoulos S, et al. Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich’s ataxia: an exploratory, open-label, dose-escalation study. Lancet. 2014;384:504–513.
   PubMed Web of Science ®Google Scholar
• Bidichandani SI, Ashizawa T, Patel PI. The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure. Am J Hum Genet. 1998;62.1:111–121.
   Web of Science ®Google Scholar
• Groh M, Lufino MMP, Wade-Martins R, et al. R-loops associated with triplet repeat expansions promote gene silencing in Friedreich ataxia and fragile X syndrome. PLoS Genet. 2014;10:e1004318.
   PubMed Web of Science ®Google Scholar
• Li L, Matsui M, Corey DR. Activating frataxin expression by repeat-targeted nucleic acids. Nat Commun. 2016;7:10606.
   PubMed Web of Science ®Google Scholar
• Ozsolak F, Sandhu K, Wood S. et al. Targeting the GAA-repeat region with oligonucleotides for the treatment of Friedreich’s ataxia. Presented at the International Ataxia Research Conference (ARC); Windsor, UK; 2015.
   Google Scholar
• Chiriboga CSK, Darras BT, Iannaccone ST. Results from a phase 1 study of nusinersen (ISIS-SMNRX) in children with spinal muscular atrophy. Neurology. 2016;86(10):890–897.
   PubMed Web of Science ®Google Scholar
• Ottesen EW. ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy. Transl Neurosci. 2017;8:1–6.
   PubMed Web of Science ®Google Scholar
• Sardone V, Zhou H, Muntoni F, et al. Antisense oligonucleotide-based therapy for neuromuscular disease. Molecules. 2017;22(4):563.
   Web of Science ®Google Scholar
• Hayashi G, Jasoliya M, Saccà F, et al. Dimethyl fumarate mediates Nrf2-dependent mitochondrial biogenesis in mice and humans. Hum Mol Genet. 2017. DOI:10.1093/hmg/ddx167
   PubMed Web of Science ®Google Scholar
• Evans-Galea MV, Lockhart PJ, Galea CA, et al. Beyond loss of frataxin: the complex molecular pathology of Friedreich ataxia. Discov Med. 2014;17(91):25–35.
   PubMed Web of Science ®Google Scholar
• Koeppen AH, Ramirez RL, Becker AB, et al. Dorsal root ganglia in Friedreich ataxia: satellite cell proliferation and inflammation. Acta Neuropathol Commun. 2016;4:46.
   PubMed Web of Science ®Google Scholar
• Michael S, Petrocine SV, Qian J, et al. Iron and iron-responsive proteins in the cardiomyopathy of Friedreich’s ataxia. Cerebellum. 2006;5(4):257–267.
   PubMed Web of Science ®Google Scholar
• Shinnick JE, Isaacs CJ, Vivlaid S, et al. Friedreich ataxia and nephrotic syndrome: a series of two patients. BMC Neurol. 2016;16(3):1–6.
   PubMed Web of Science ®Google Scholar
• Pane M, Fanelli L, Mazzone ES, et al. Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: a multicentric longitudinal study using the performance of upper limb test. Neuromuscul Disord. 2015;25(10):749–753.
   PubMed Web of Science ®Google Scholar
• Reeves EK, Rayavarapu S, Damsker JM, et al. Glucocorticoid analogues: potential therapeutic alternatives for treating inflammatory muscle diseases. Endocr Metab Immune Disord Drug Targets. 2012;12(1):95–103.
   PubMedGoogle Scholar
• ClinicalTrials.gov Methylprednisolone Treatment of Friedreich Ataxia. Available from: https://clinicaltrials.gov/ct2/show/NCT02424435
   Google Scholar
• Miranda CJ, Santos MM, Ohshima K, et al. Frataxin overexpressing mice. FEBS Lett. 2004;572(1–3):281–288.
   PubMed Web of Science ®Google Scholar
• Li Y, Polak U, Bhalla AD, et al. Excision of expanded GAA repeats alleviates the molecular phenotype of Friedreich’s ataxia. Mol Ther. 2015;23(6):1055–1065.
   PubMed Web of Science ®Google Scholar
• Ouellet DL, Cherif K, Rousseau J, et al. Deletion of the GAA repeats from the human frataxin gene using the CRISPR-Cas9 system in YG8R-derived cells and mouse models of Friedreich ataxia. Gene Ther. 2017;24(5):265–274.
   PubMed Web of Science ®Google Scholar
• Perdomini M, Belbellaa B, Monassier L, et al. Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich’s ataxia. Nat Med. 2014;20(5):542–547.
   PubMed Web of Science ®Google Scholar
• Gérard C, Xiao X, Filali M, et al. An AAV9 coding for frataxin clearly improved the symptoms and prolonged the life of Friedreich ataxia mouse models. Mol Ther Meth Clin. 2014;1:14044.
   PubMed Web of Science ®Google Scholar
• Gomez-Sebastian S, Gimenez-Cassina A, Diaz-Nido J, et al. Infectious delivery and expression of a 135 kb human FRDA genomic DNA locus complements Friedreich’s ataxia deficiency in human cells. Mol Ther. 2007;15(2):248–254.
   PubMed Web of Science ®Google Scholar
• Gimenez-Cassina A, Wade-Martins R, Gomez-Sebastian S, et al. Infectious delivery and long-term persistence of transgene expression in the brain by a 135-kb iBAC-FXN genomic DNA expression vector. Gene Ther. 2011;18(10):1015–1019.
   PubMed Web of Science ®Google Scholar
• Lim F, Palomo GM, Mauritz C, et al. Functional recovery in a Friedreich’s ataxia mouse model by frataxin gene transfer using an HSV-1 amplicon vector. Mol Ther. 2007;15(6):1072–1078.
   PubMed Web of Science ®Google Scholar
• Chapdelaine P, Coulombe Z, Chikh A, et al. A potential new therapeutic approach for Friedreich ataxia: induction of frataxin expression with TALE proteins. Mol Ther Nucleic Acids. 2013;2:e119.
   PubMedGoogle Scholar